Bristol-Myers Squibb
BMY
2,541 hedge funds and large institutions have $96.7B invested in Bristol-Myers Squibb in 2026 Q2 according to their latest regulatory filings, with 176 funds opening new positions, 1,008 increasing their positions, 1,011 reducing their positions, and 160 closing their positions.
68% more capital inflows, than outflows
Capital inflows: $8.4B | Capital outflows: $5B
10% more first-time investments, than exits
New positions opened: 176 | Existing positions closed: 160
2.75% more ownership
Funds ownership: 79.34% → 82.09% (+2.8%)
1% more call options, than puts
Call options by funds: $1.51B | Put options by funds: $1.5B
0% less repeat investments, than reductions
Existing positions increased: 1,008 | Existing positions reduced: 1,011
0% less funds holding
Funds holding: 2,552 → 2,541 (-11)
42% less funds holding in top 10
Funds holding in top 10: 36 → 21 (-15)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.23B |
| 2 |
BlackRock
New York
|
+$500M |
| 3 |
Charles Schwab
San Francisco,
California
|
+$372M |
| 4 |
Nordea Investment Management
Stockholm,
Sweden
|
+$346M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$323M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.19B |
| 2 |
Millennium Management
New York
|
-$333M |
| 3 |
Dodge & Cox
San Francisco,
California
|
-$263M |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
-$222M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$211M |
BMY Hedge Fund Activity: Q2 2026 in Review
2,541 of the 8,375 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q2 2026, worth a combined $96.7B — down 1.4% from $98.1B a quarter earlier.
Buyers outnumbered sellers: 176 funds opened new BMY positions and 160 closed out — a net gain of 16 holders — while 1,008 added to existing stakes and 1,011 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $1.23B. The largest seller was JP Morgan Chase, cutting an estimated $1.19B.
- 2,541 institutional investors held Bristol-Myers Squibb (BMY) as of Q2 2026, down from 2,552 in Q1 2026.
- Funds reported $96.7B of Bristol-Myers Squibb stock for Q2 2026, down 1.4% quarter-over-quarter.
- 176 funds opened new Bristol-Myers Squibb positions in Q2 2026 and 160 closed out, a net change of +16 holders.
- The largest Bristol-Myers Squibb buyer in Q2 2026 was T. Rowe Price Associates, an estimated $1.23B added.
- The largest Bristol-Myers Squibb seller in Q2 2026 was JP Morgan Chase, an estimated $1.19B sold.
Based on aggregated 13F filings for Q2 2026.